FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2106-2108 May 17, 2007 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by McMahon, G. T. PubMed Citation

To the Editor: An important uncertainty about treatment with inhaled insulin is the potentially increased risk of lung cancer. In their Clinical Therapeutics article on inhaled insulin for diabetes mellitus, McMahon and Arky (Feb. 1 issue)¹ report that short-term studies in animals have not shown a substantial effect on cell-proliferation indexes in the alveolar or bronchiolar areas of the lung. This is not quite correct. One of the short-term studies reports an increased rate of mitosis induced by inhaled insulin in rats.²

Presumably in response to this finding, Pfizer, the manufacturer of a dry-powder formulation of human insulin, proposed to . . . [Full Text of this Article]

This article has been cited by other articles:

• Dekkers, B. G. J., Schaafsma, D., Tran, T., Zaagsma, J., Meurs, H. (2009). Insulin-Induced Laminin Expression Promotes a Hypercontractile Airway Smooth Muscle Phenotype. Am. J. Respir. Cell Mol. Bio. 41: 494-504 [Abstract] [Full Text]